Vasu Nair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Vasu Nair has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Suresh Pal
Department of Chemistry, The University of Iowa, Iowa City, IA 52242, USA
2 shared publicationsBindu Bera
Department of Chemistry, The University of Iowa, Iowa City, IA 52242, USA
1 shared publicationJianzhong Zhang
Department of Chemistry, The University of Iowa, Iowa City, IA 52242 USA
1 shared publicationLea Pickering
Department of Chemistry, The University of Iowa, Iowa City, IA 52242 USA
1 shared publicationQi Chao
Department of Chemistry, The University of Iowa, Iowa City, IA 52242 USA
1 shared publicationSanjib Bera
Department of Chemistry, The University of Iowa, Iowa City, IA 52242, U.S.A. (fax: (319) 353‐2621)
1 shared publication
Latest Publications
- 1 November 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 10 (11) , 3615-3618
Inhibition of inosine monophosphate dehydrogenase (IMPDH) by the antiviral compound, 2-vinylinosine monophosphate
- 1 November 2002
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 10 (11) , 3615-3618
Inhibition of inosine monophosphate dehydrogenase (IMPDH) by the antiviral compound, 2-vinylinosine monophosphate
- 25 April 2002
- Published by Wiley in Reviews in Medical Virology
- Vol. 12 (3) , 179-193
HIV integrase as a target for antiviral chemotherapy
One of the three key enzymes encoded by the pol gene of HIV is a Mr 32 000 protein called HIV integrase. This viral enzyme is involved in the integration of HIV DNA into host chromosomal DNA. There appears to be no functional equivalent of the enzyme in human cells. The biochemical mechanism of integration of HIV DNA into the host cell genome involves a carefully defined sequence of DNA tailoring (3′‐processing) and coupling (joining or integration) reactions. In spite of some effort in this area targeted at the discovery of therapeutically useful inhibitors of this viral enzyme, there are no drugs for HIV/AIDS in clinical use where the mechanism of action is inhibition of HIV integrase. Thus, new knowledge on inhibitors of this enzyme is of critical importance in the anti‐HIV drug discovery area. The focus of this review will be on several classes of compounds, including nucleotides, dinucleotides, oligonucleotides and miscellaneous small molecules such as heterocyclic systems, natural products, diketo acids and sulfones, that have been discovered as inhibitors of HIV integrase. Special emphasis in the review will be placed on discoveries from my laboratory on HIV integrase inhibitors that are non‐natural, nuclease‐resistant dinucleotides. Comments on future directions and the prospects for developing integrase inhibitors as therapeutic antiviral agents are discussed. Copyright © 2002 John Wiley & Sons, Ltd.
- 25 April 2002
- Published by Wiley in Reviews in Medical Virology
- Vol. 12 (3) , 179-193
HIV integrase as a target for antiviral chemotherapy
One of the three key enzymes encoded by the pol gene of HIV is a Mr 32 000 protein called HIV integrase. This viral enzyme is involved in the integration of HIV DNA into host chromosomal DNA. There appears to be no functional equivalent of the enzyme in human cells. The biochemical mechanism of integration of HIV DNA into the host cell genome involves a carefully defined sequence of DNA tailoring (3′‐processing) and coupling (joining or integration) reactions. In spite of some effort in this area targeted at the discovery of therapeutically useful inhibitors of this viral enzyme, there are no drugs for HIV/AIDS in clinical use where the mechanism of action is inhibition of HIV integrase. Thus, new knowledge on inhibitors of this enzyme is of critical importance in the anti‐HIV drug discovery area. The focus of this review will be on several classes of compounds, including nucleotides, dinucleotides, oligonucleotides and miscellaneous small molecules such as heterocyclic systems, natural products, diketo acids and sulfones, that have been discovered as inhibitors of HIV integrase. Special emphasis in the review will be placed on discoveries from my laboratory on HIV integrase inhibitors that are non‐natural, nuclease‐resistant dinucleotides. Comments on future directions and the prospects for developing integrase inhibitors as therapeutic antiviral agents are discussed. Copyright © 2002 John Wiley & Sons, Ltd.
- 1 November 2000
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (11) , 2939-2947
Anti-Human Immunodeficiency Virus Activities of Nucleosides and Nucleotides: Correlation with Molecular Electrostatic Potential Data
Examination of the anti-human immunodeficiency virus (HIV) data of some normal and isomeric dideoxynucleosides (ddNs and isoddNs), their three-dimensional (3-D) electron density patterns, their electrostatic potential surfaces (EPS), and their conformational maps reveals some interesting correlations. For example, the EPS of (S,S)-isoddA shows regions of high and low electrostatic potential remarkably similar to those of β-d-3′-azido-3′-deoxythymidine (β-d-AZT), (−)-oxetanocin A, and (−)-carbovir. Such correlations involving EPS data and anti-HIV activity were also found with many other active nucleosides. Conversely, inactive compounds had EPS different from those of compounds in the same series that were active. For example, apio-ddNs, which are inactive against HIV, exhibit clear differences in electrostatic potential and 3-D electron density shape from isoddNs that are active against HIV. Additionally, the inactivity of (S,S)-isoddC and (S,S)-isoddT can be correlated convincingly with a combination of their EPS data and their conformational energy maps. The electrostatic potential distributions of active nucleoside triphosphates show remarkable correlations. For example, (S,S)-isoddATP, AZT triphosphate (AZTTP), and oxetanocin A TP have similar 3-D electron density surface patterns and similar high and low regions of electrostatic potential, which may suggest that these compounds proceed through related mechanisms in their interactions with, and inhibition of, HIV reverse transcriptase (RT). Docking of AZTTP, (S,S)-isoddATP, and other active triphosphates into the active site of HIV RT and calculation of the EPS of both the nucleotide and the active site show that there is excellent matching between inhibitor and enzyme binding site EPS data. The structure-activity profile discovered has contributed to the development of a first predictive quantitative structure-activity relationship analysis in the area.
- 1 November 2000
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (11) , 2939-2947
Anti-Human Immunodeficiency Virus Activities of Nucleosides and Nucleotides: Correlation with Molecular Electrostatic Potential Data
Examination of the anti-human immunodeficiency virus (HIV) data of some normal and isomeric dideoxynucleosides (ddNs and isoddNs), their three-dimensional (3-D) electron density patterns, their electrostatic potential surfaces (EPS), and their conformational maps reveals some interesting correlations. For example, the EPS of (S,S)-isoddA shows regions of high and low electrostatic potential remarkably similar to those of β-d-3′-azido-3′-deoxythymidine (β-d-AZT), (−)-oxetanocin A, and (−)-carbovir. Such correlations involving EPS data and anti-HIV activity were also found with many other active nucleosides. Conversely, inactive compounds had EPS different from those of compounds in the same series that were active. For example, apio-ddNs, which are inactive against HIV, exhibit clear differences in electrostatic potential and 3-D electron density shape from isoddNs that are active against HIV. Additionally, the inactivity of (S,S)-isoddC and (S,S)-isoddT can be correlated convincingly with a combination of their EPS data and their conformational energy maps. The electrostatic potential distributions of active nucleoside triphosphates show remarkable correlations. For example, (S,S)-isoddATP, AZT triphosphate (AZTTP), and oxetanocin A TP have similar 3-D electron density surface patterns and similar high and low regions of electrostatic potential, which may suggest that these compounds proceed through related mechanisms in their interactions with, and inhibition of, HIV reverse transcriptase (RT). Docking of AZTTP, (S,S)-isoddATP, and other active triphosphates into the active site of HIV RT and calculation of the EPS of both the nucleotide and the active site show that there is excellent matching between inhibitor and enzyme binding site EPS data. The structure-activity profile discovered has contributed to the development of a first predictive quantitative structure-activity relationship analysis in the area.
- 2 October 2000
- Published by Elsevier in Biochemical Pharmacology
- Vol. 60 (10) , 1505-1508
Phosphorylation of the anti-HIV compound (S,S)-isodideoxyadenosine by human recombinant deoxycytidine kinase
- 2 October 2000
- Published by Elsevier in Biochemical Pharmacology
- Vol. 60 (10) , 1505-1508
Phosphorylation of the anti-HIV compound (S,S)-isodideoxyadenosine by human recombinant deoxycytidine kinase
- 5 July 2000
- Published by Wiley in Helvetica Chimica Acta
- Vol. 83 (7) , 1398-1407
Isonucleosides with Exocyclic Methylene Groups
- 5 July 2000
- Published by Wiley in Helvetica Chimica Acta
- Vol. 83 (7) , 1398-1407
Isonucleosides with Exocyclic Methylene Groups
- 11 October 1999
- Published by Elsevier in Tetrahedron
- Vol. 55 (40) , 11803-11818
Synthesis of isomeric nucleoside phosphonates: Cyclic analogs of the anti-HIV active compound, PMEA
- 11 October 1999
- Published by Elsevier in Tetrahedron
- Vol. 55 (40) , 11803-11818
Synthesis of isomeric nucleoside phosphonates: Cyclic analogs of the anti-HIV active compound, PMEA
- 1 March 1998
- Published by Elsevier in Tetrahedron
- Vol. 54 (13) , 3113-3124
Concise and stereospecific synthesis of novel bicyclic dideoxynucleosides as potential antiviral agents
- 1 March 1998
- Published by Elsevier in Tetrahedron
- Vol. 54 (13) , 3113-3124
Concise and stereospecific synthesis of novel bicyclic dideoxynucleosides as potential antiviral agents